Skip to content

Abnormal B Cell Proliferation C4531167

Published: July 22, 2026Updated: August 20, 2026

Uncontrolled or excessive growth of B cells, which are white blood cells in the immune system. Can affect both children and adults. Treatment depends on the specific cause and may include monitoring or therapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Recurrent Infections

Frequent or unusual infections due to impaired immune function from abnormal B-cell proliferation affecting normal immune cell function.

Seek immediate care if you develop fever above 101°F (38.3°C), severe infections, or infections that do not respond to usual treatment.

!

Fever

Persistent or recurrent fever without obvious infection, caused by the disease process itself or associated immune dysfunction.

Seek immediate medical attention for fever above 101°F (38.3°C) lasting more than 24 hours, especially if accompanied by chills, confusion, or other concerning symptoms.

Fatigue

(constitutional)

Persistent tiredness and weakness that does not improve with rest, often due to anemia or metabolic changes from abnormal B-cell proliferation.

Frequency: 70-80% of patients

Lymphadenopathy

(constitutional)

Enlarged lymph nodes, typically painless, often felt in the neck, armpits, or groin areas due to abnormal B-cell accumulation.

Frequency: 60-70% of patients

Night Sweats

(constitutional)

Excessive sweating during sleep that may soak through clothing or bedding, often associated with constitutional symptoms of the underlying condition.

Frequency: 30-50% of patients

Unexplained Weight Loss

(constitutional)

Significant weight loss (more than 5% of body weight) without changes in diet or exercise, often due to metabolic effects of the disease.

Frequency: 30-40% of patients

Easy Bruising

(hematologic)

Bruising or petechiae (small red-purple spots) appearing easily due to low platelet count from bone marrow involvement.

Frequency: 20-30% of patients

Splenomegaly

(hematologic)

Enlarged spleen causing fullness in the upper left abdomen, early satiety, or discomfort due to accumulation of abnormal B-cells.

Frequency: 25-35% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Immunomodulatory therapy

Targeted biological agents that regulate B-cell proliferation and function. Treatment requires careful monitoring of hematological parameters and immune function to assess therapeutic response.

medication
3

Serial hematological surveillance

Regular blood work including flow cytometry to track B-cell populations and proliferation markers. Enables early detection of disease progression or treatment response.

monitoring

Additional treatment options

Therapeutic apheresis

Procedures such as plasmapheresis may be used to remove pathogenic antibodies or abnormal cells from circulation in severe cases.

procedure

Infection prevention protocols

Enhanced hygiene practices, vaccination when appropriate, and avoidance of known infection exposures given potential immunocompromised state.

lifestyle

Stress reduction and psychological support

Mind-body techniques including meditation and counseling to support immune function and cope with chronic disease management.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal B Cell Proliferation C4531167?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. International Agency for Research on Cancer. Lyon, 2017.

guideline2017View source →
2

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 4.2024.

guideline2024View source →
3

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 3.2024.

guideline2024View source →
4

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the WHO classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.

review2016View source →
5

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.

consensus2014View source →
6

Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251-262.

review2005View source →
7

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.

meta_analysis2018View source →
8

Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.

clinical_trial2016View source →
9

Shustik J, Bence A, Bhella S, et al. Policy statement on B-cell lymphoproliferative disorders. Canadian Society of Hematology. 2020.

position_statement2020View source →
10

Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology, 7th Edition. Wiley-Blackwell; 2016.

textbook2016View source →

Medication Comparisons

Compare medications used to treat Abnormal B Cell Proliferation C4531167. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy